Recurrent Childhood Acute Lymphoblastic Leukemia Completed Phase 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01427881Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesTreatment
NCT00873093Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTreatment
NCT01093586Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment
NCT01177371High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaTreatment